Evidence map›Paper›PMID 21350120›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2011

Disrupted myosin cross-bridge cycling kinetics triggers muscle weakness in nebulin-related myopathy.

Julien Ochala, Vilma-Lotta Lehtokari, Hiroyuki Iwamoto, Meishan Li, Han-Zhong Feng, Jian-Ping Jin, Naoto Yagi, Carina Wallgren-Pettersson, Isabelle Pénisson-Besnier, Lars Larsson

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Nebulin: big protein with big responsibilities.Journal of muscle research and cell motility · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Nebulin stiffens the thin filament and augments cross-bridge interaction in skeletal muscle.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Nebulin, a multi-functional giant.The Journal of experimental biology · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Julien OchalaDepartment of Neuroscience, Clinical Neurophysiology, Uppsala University Hospital, Entrance 85, 3rd floor, SE-751 85 Uppsala, Sweden. julien.ochala@neuro.uu.se
Vilma-Lotta Lehtokari
Hiroyuki Iwamoto
Meishan Li
Han-Zhong Feng
Jian-Ping Jin
Naoto Yagi
Carina Wallgren-Pettersson
Isabelle Pénisson-Besnier
Lars Larsson
Uppsala University · SEInstitute of Genetics · HUJapan Synchrotron Radiation Research Institute · JPWayne State University · USCentre Hospitalier Universitaire d'Angers · FR

Funding

Role of Troponin T Isoforms in Nemaline MyopathyR01AR048816 · NIAMS · WAYNE STATE UNIVERSITY · PI JIN, JIAN-PING · 2003 to 2014
$3.2M
NIAMS NIH HHS AR-048816NIAMS NIH HHS R01 AR048816
6 · The paper itself

Abstract

Nebulin is a giant protein expressed at high levels in skeletal muscle. Mutations in the nebulin gene (NEB) lead to muscle weakness and various congenital myopathies. Despite increasing clinical and scientific interest, the pathogenesis of weakness remains unknown. The present study, therefore, aims at unraveling the underlying molecular mechanisms. Hence, we recorded and analyzed the mechanics as well as the X-ray diffraction patterns of human membrane-permeabilized single muscle fibers expressing nebulin mutations. Results demonstrated that, during contraction, the cycling rate of myosin heads attaching to actin is dramatically perturbed, causing a reduction in the fraction of myosin-actin interactions in the strong binding state. This phenomenon prevents complete thin-filament activation, more especially proper and full tropomyosin movement, further limiting additional binding of myosin cross-bridges. At the cell level, this reduces the force-generating capacity and, overall, provokes muscle weakness. To reverse such a negative cascade of events, future potential therapeutic interventions should, therefore, focus on the triggering component, the altered myosin cross-bridge cycling kinetics.

Indexed as

AdultGene Expression RegulationHumansKineticsMaleMiddle AgedMuscle ProteinsMuscle, SkeletalMuscle WeaknessMutationMyopathies, NemalineMyosinsX-Ray DiffractionMuscle ProteinsMyosinsnebulin

Identifiers

PMID21350120
PMCPMC3219215
OpenAlexW2001880605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.